Marker Therapeutics Inc. (MRKR)
2.63
0.09 (3.54%)
At close: Jan 15, 2025, 1:38 PM
undefined% (undefined)
| Bid | 2.59 |
| Market Cap | 28.21M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.07 |
| PE Ratio (ttm) | -2.46 |
| Forward PE | n/a |
| Analyst | Strong Buy |
| Ask | 2.68 |
| Volume | 28,811 |
| Avg. Volume (20D) | 56,280 |
| Open | 2.58 |
| Previous Close | 2.54 |
| Day's Range | 2.58 - 2.79 |
| 52-Week Range | 2.44 - 5.99 |
| Beta | undefined |
About MRKR
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 16, 2002
Employees 8
Stock Exchange NASDAQ
Ticker Symbol MRKR
Analyst Forecast
According to 1 analyst ratings, the average rating for MRKR stock is "Strong Buy." The 12-month stock price forecast is $19, which is an increase of 621.06% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Marker Therapeutics Inc. is scheduled to release its earnings on Mar 25, 2025,
during market hours.
Analysts project revenue of $1.00M, reflecting a -5.39% YoY shrinking and earnings per share of -0.28, making a -6.67% decrease YoY.
Analysts project revenue of $1.00M, reflecting a -5.39% YoY shrinking and earnings per share of -0.28, making a -6.67% decrease YoY.
3 weeks ago ·
Source
-7.44%
Marker Therapeutics shares are trading lower. The ...
Unlock content with
Pro Subscription
4 weeks ago ·
Source
+17.68%
Marker Therapeutics shares are trading higher after the company announced it won a $9.5 million grant to study pancreatic cancer therapy.